On-demand Inhaled Corticosteroid and Fast-onset Beta-2 Agonist Combination Therapy Versus Conventional Treatment for Mild to Moderate Asthma: A Non-inferiority, Network Meta-analysis
-
- ANDO Koichi
- Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine Showa University Dental Hospital Medical Clinic
-
- TANAKA Akihiko
- Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine
-
- YOKOE Takuya
- Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine
-
- OHNISHI Tsukasa
- Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine
-
- INOUE Shin
- Showa University Dental Hospital Medical Clinic
-
- SAGARA Hironori
- Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine
この論文をさがす
抄録
The aim of this study was to assess the non-inferiority of on-demand (OD) inhaled corticosteroid (ICS) and fast-onset beta-2 agonist (FOBA) combination therapy. Although the guidelines recommend regular inhalation of ICS and long-acting beta-2 agonist (LABA), we investigated whether OD-ICS/FOBA is as effective as regular inhalation. A network meta-analysis of randomized controlled trials was conducted to inspect the non-inferiority of OD-ICS/FOBA efficacy compared with conventional best practice, i.e. regular low – to medium-dose ICS with or without LABA, plus OD short-acting beta-2 agonist (REG-ICS+OD-SABA or REG-ICS/LABA+OD-SABA) in patients with mild to moderate asthma. PubMed, the Cochrane library database, and Scopus were searched to identify relevant articles. Outcome measures were the incidence of asthma exacerbation or aggravation. A network meta-analysis was performed to estimate risk ratios (RRs) with 95% confidence intervals (CIs) and the probability of being the best treatment for the outcome. Four randomized controlled trials of treatment for mild to moderate asthma met the criteria and were included in the study. We could not demonstrate non-inferiority of OD-ICS/FOBA to REG-ICS+OD-SABA (RR, 1.17; 95% CI, 0.61 to 2.26) or to REG-ICS/LABA+OD-SABA (RR, 1.47; 95% CI, 0.79 to 2.71) for mild to moderate asthma. The probability of being the best treatment to reduce asthma exacerbation or aggravation was 10.5% for OD-ICS/FOBA, 10.3% for REG-ICS+OD-SABA, and 79.3% for REG-ICS/LABA+OD-SABA. Surface under the cumulative ranking (SUCRA) curves were 0.4, 0.2 and 0.9 for OD-ICS/FOBA, REG-ICS+OD-SABA, and REG-ICS/LABA+OD-SABA, respectively. Although non-inferiority of OD-ICS/FOBA to conventional best practice was not shown, SUCRA was higher for OD-ICS/FOBA than for REG-ICS+OD-SABA. From these results, we propose that OD-ICS/FOBA can be an effective alternative to REG-ICS+OD-SABA to reduce asthma exacerbation or aggravation in patients with mild to moderate asthma.
収録刊行物
-
- The Showa University Journal of Medical Sciences
-
The Showa University Journal of Medical Sciences 29 (1), 17-26, 2017
昭和大学学士会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204373577600
-
- NII論文ID
- 130005864963
-
- NII書誌ID
- AA10781651
-
- ISSN
- 21850968
- 09156380
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- IRDB
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可